Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2004-03-26
2009-12-15
Chernyshev, Olga N (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C530S326000, C530S300000, C530S332000, C424S185100
Reexamination Certificate
active
07632816
ABSTRACT:
The present invention is directed to a method of preventing or treating Alzheimer's Disease or of inhibiting accumulation of amyloid-β deposits in a subject by administering to the subject an agent which inhibits interaction between amyloid-β and proteins which chaperone amyloid-β under conditions effective to prevent or treat Alzheimer's Disease in the subject or to inhibit accumulation of amyloid-β deposits in the subject's brain, respectively. Another embodiment of the present invention relates to a method of inhibiting interaction between apolipoprotein E and amyloid-β by administering an agent which blocks interaction of apolipoprotein E and amyloid-β under conditions effect to block such interaction.
REFERENCES:
patent: 5187153 (1993-02-01), Cordell et al.
patent: 5948763 (1999-09-01), Soto-Jara et al.
patent: WO 99/27944 (1999-10-01), None
FASEB Journal, 1995, vol. 9, No. 5, pp. 366-370.
Drug Aging, 2002, 19 (7), pp. 487-494.
Sato et al., 1998, Nature Medicine, 1998, vol. 4, 7, pp. 822-826.
Bales et al., “Apolipoprotein E is Essential for Amyloid Deposition in the APPV717F Transgenic Mouse Model of Alzheimer's Disease,” Proc. Natl. Acad. Sci. (USA) 96:15233-15238 (1999).
Bales et al., “Lack of Apolipoprotein E Dramatically Reduces Amyloid Beta-Peptide Deposition,” Nature Gen. 17:263-264 (1997).
Barrow et al., “Solution Conformations and Aggregational Properties of Synthetic Amyloid Beta-Peptides of Alzheimer's Disease. Analysis of Circular Dichroism Spectra,” J. Mol. Biol. 225:1075-1093 (1992).
Buttini et al., “Modulation of Alzheimer-Like Synaptic and Cholinergic Deficits in Transgenic Mice by Human Apolipoprotein E Depends on Isoform, Aging and Overexpression of Amyloid Beta Peptides but not on Plaque Formation,” J. Neurosci. 22:10539-10548 (2002).
Castano et al., “Fibrillogenesis in Alzheimer's Disease of Amyloid Beta Peptides and Apolipoprotein E,” Biochem. J. 306:599-604 (1995).
Demattos et al., “ApoE and Clusterin Cooperatively Suppress ABeta Levels and Deposition: Evidence that ApoE Regulates Extracellular ABeta Metabolism In Vivo,” Neuron 41:193-202 (2004).
Golabek et al., “Amyloid Beta Binding Proteins In Vitro and In Normal Human Cerebrospinal Fluid,” Neurosci. Lett. 191:79-82 (1995).
Golabek et al., “The Interaction Between Apolipoprotein E and Alzheimer's Amyloid Beta-peptide is Dependent on Beta-Peptide Conformation,” J. Biol. Chem. 271:10602-10606 (1996).
Holtzman et al., “Apolipoprotein E Isoform-Dependent Amyloid Deposition and Neuritic Degeneration in a Mouse Model of Alzheimer's Disease,” Proc. Natl. Acad. Sci. (USA) 97:2892-2897 (2000).
Holtzman et al., “Expression of Human Apolipoprotein E Reduces Amyloid-Beta Deposition in a Mouse Model of Alzheimer's Disease,” J. Clin. Invest. 103:R15-R21 (1999).
Ji et al., “Amyloid Beta40/42 Clearance Across the Blood-Brain Barrier Following Intra-Ventricular Injections in Wild-Type, ApoE Knock-Out and Human ApoE3 or E4 Expressing Transgenic Mice,” J. Alz. Dis. 3:23-30 (2001).
Ji et al., “Apolipoprotein E Isoform-Specific Regulation of Dendritic Spine Morphology in Apolipoprotein E Transgenic Mice and Alzheimer's Disease Patients,” Neuroscience 122:305-315 (2003).
Ma et al., “Alzheimer ABeta Neurotoxicity: Promotion by Antichymotrypsin, ApoE4; Inhibition by ABeta-Related Peptides,” Neurobiol. Aging 17:773-780 (1996).
Ma et al., “Amyloid-Associated Proteins Alpha 1-Antichymotrypsin and Apolipoprotein E Promote Assembly of Alzheimer Beta-protein into Filaments,” Nature 372:92-94 (1994).
Naslund et al. “Characterization of Stable Complexes Involving Apolipoprotein E and the Amyloid Beta Peptide in Alzheimer's Disease Brain,” Neuron 15:219-228 (1995).
Sadowski et al. “A Synthetic Peptide Blocking the Apolipoprotein E/Beta-Amyloid Binding Mitigates Beta-Amyloid Toxicity and Fibril Formation In Vitro and Reduces Beta-Amyloid Plaques in Transgenic Mice,” Am. J. Pathol. 165:937-948 (2004).
Selkoe, “The Origins of Alzheimer Disease: A is for Amyloid,” JAMA 283:1615-1617 (2000).
Shuvaev and Siest, “Interaction Between Human Amphipathic Apolipoproteins and Amyloid Beta-peptide: Surface Plasmon Resonance Studies,” FEBS Lett. 383:9-12 (1996).
Sigurdsson et al., “Immunization with a Nontoxic/Nonfibrillar Amyloid-Beta Homologous Peptide Reduces Alzheimer's Disease Associated Pathology in Transgenic Mice,” Am. J. Pathol. 159:439-447 (2001).
Sigurdsson et al., “In vivo Reversal of Amyloid Beta Lesions in Rat Brain,” J. Neuropath. Exp. Neurol. 59:11-17 (2000).
Soto et al., “Alzheimer's Beta-Amyloid Peptide is Conformationally Modified by Apolipoprotein E In Vitro,” Neuroreport 7:721-725 (1996).
Strittmatter et al., “Apolipoprotein E: High-Avidity Binding to Beta-amyloid and Increased Frequency of Type 4 Allele in Late-onset Familial Alzheimer Disease,” Proc. Natl. Acad. Sci. (USA) 90:1977-1981 (1993).
Wisniewski et al., “Acceleration of Alzheimer's Fibril Formation by Apolipoprotein E In Vitro,” Am. J. Pathol. 145:1030-1035 (1994).
Wisniewski and Frangione, “Apolipoprotein E: A Pathological Chaperone Protein in Patients with Cerebral and Systemic Amyloid,” Neurosci. Lett. 135:235-238 (1992).
Wisniewski et al., “Apolipoprotein E: Binding to Soluble Alzheimer's Beta-Amyloid,” Biochem. Biophys. Res. Commun. 192:359-365 (1993).
Wisniewski et al., “Diffuse, Lake-like Amyloid-Beta Deposits in the Parvopyramidal Layer of the Presubiculum in Alzheimer Disease,” Journal of Neuropathology & Experimental Neurology 57:674-683 (1998).
Zlokovic “Cerebrovascular Transport of Alzheimer's Amyloid Beta and Apolipoproteins J and E: Possible Anti-Amyloidogenic Role of the Blood-Brain Barrier,” Life Sci. 59:1483-1497 (1996).
Zlokovic et al., “Brain Uptake of Circulating Apolipoproteins J and E Complexed to Alzheimer's Amyloid Beta,” Biochem. Biophys. Res. Commun. 205:1431-1437 (1994).
Andersen et al., “Do Nonsteroidal Anti-inflammatory Drugs Decrease the Risk for Alzheimer's Disease?” Neurology 45:1441-5 (1995).
Selkoe, “Translating Cell Biology into Therapeutic Advances in Alzheimer's Disease,” Nature 399:A23-31 (1999).
Frangione Blas
Sadowski Marcin
Sigurdsson Einar M.
Wisniewski Thomas
Chernyshev Olga N
New York University
Nixon & Peabody LLP
LandOfFree
Treatment of Alzheimer amyloid deposition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of Alzheimer amyloid deposition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of Alzheimer amyloid deposition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4126726